🇺🇸 FDA

Intelligence · Clinical Pipeline

Boehringer Ingelheim Pipeline

All ClinicalTrials.gov programs at Boehringer Ingelheim — phase, modality, and trial IDs.

Programs
193

Quick answer

Boehringer Ingelheim has 193 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. fixed dose combination of telmisartan+amlodipine

    Boehringer Ingelheim

    Hypertension

    phase 3 small molecule completed

    1 trial

  2. linagliptine 5 mg

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  3. nintedanib, Nintedanib, nintedanib

    Boehringer Ingelheim

    Childhood Interstitial Lung Disease

    phase 3 small molecule active

    1 trial

  4. obrixtamig

    Boehringer Ingelheim

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  5. placebo

    Boehringer Ingelheim

    Pulmonary Fibrosis

    phase 3 small molecule completed

    1 trial

  6. placebo plus docetaxel

    Boehringer Ingelheim

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  7. survodutide

    Boehringer Ingelheim

    Obesity

    phase 3 other active

    1 trial

  8. telmisartan/amlodipine 40/5 mg fixed combination

    Boehringer Ingelheim

    Hypertension

    phase 3 small molecule completed

    1 trial

  9. tiotropium

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    1 trial

  10. tiotropium + olodaterol

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    1 trial

  11. tiotropium 5mcg/day

    Boehringer Ingelheim

    Asthma

    phase 3 small molecule completed

    1 trial

  12. tiotropium high dose

    Boehringer Ingelheim

    Asthma

    phase 3 small molecule completed

    1 trial

  13. warfarin

    Boehringer Ingelheim

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  14. zongertinib

    Boehringer Ingelheim

    Lung Cancer, Non-squamous, Non-small Cell

    phase 3 small molecule active

    1 trial

  15. A Phase II, 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in patients with major depressive disorder

    Boehringer Ingelheim

    Major depressive disorder

    phase 2 other active

    1 trial

  16. Afatinib once daily (OD)

    Boehringer Ingelheim

    Breast Neoplasms

    phase 2 small molecule completed

    1 trial

  17. Avenciguat

    Boehringer Ingelheim

    Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  18. BI 1744 CL 2 µg

    Boehringer Ingelheim

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  19. BI 1810631

    Boehringer Ingelheim

    HER2-mutated or overexpressed/amplified solid tumours

    phase 2 small molecule active

    1 trial

  20. BI 1815368, BI 1815368 Placebo, BI 1815368

    Boehringer Ingelheim

    Centre-involved diabetic macular edema

    phase 2 small molecule active

    1 trial

  21. BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  22. BI 1839100, Placebo matching in size, weight, colour and shape to tablets of BI 1839100

    Boehringer Ingelheim

    Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  23. BI 3000202, BI 3000202, Placebo matching BI 3000202

    Boehringer Ingelheim

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  24. BI 3720931, BI 3720931

    Boehringer Ingelheim

    Cystic fibrosis

    phase 2 small molecule active

    1 trial

  25. BI 3720931, Gadovist 1.0 mmol/ml solution for injection, Solvent for dilution for BI 3720931 inhaler solution, BI 3720931

    Boehringer Ingelheim

    Cystic fibrosis

    phase 2 small molecule active

    1 trial

  26. BI 456906

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  27. BI 655130

    Boehringer Ingelheim

    Dermatitis, Atopic

    phase 2 small molecule completed

    1 trial

  28. BI 671800

    Boehringer Ingelheim

    Asthma

    phase 2 small molecule completed

    1 trial

  29. BI 685509, Placebo matching BI 685509 PRD9566383, Placebo matching BI 685509 PRD9566375, BI 685509, BI 685509, Placebo matching BI 685509 PRD9566374

    Boehringer Ingelheim

    clinically significant portal hypertension (CSPH) in decompensated cirrhosis due to non-cholestatic liver disease

    phase 2 small molecule active

    1 trial

  30. BI 690517, Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat

    Boehringer Ingelheim

    chronic kidney disease

    phase 2 small molecule active

    1 trial

  31. BI 764198

    Boehringer Ingelheim

    Proteinuric Kidney Diseases

    phase 2 small molecule active

    1 trial

  32. BI 764198, Placebo to match BI 764198, BI 764198, BI 764198

    Boehringer Ingelheim

    Focal segmental glomerulosclerosis

    phase 2 small molecule active

    1 trial

  33. BI 764524, Sham Injection Procedure

    Boehringer Ingelheim

    Diabetic retinopathy

    phase 2 small molecule active

    1 trial

  34. BI 907828, BI 907828, BI 907828

    Boehringer Ingelheim

    Solid tumours

    phase 2 small molecule active

    1 trial

  35. Herceptin 150 mg powder for concentrate for solution for infusion, Enhertu 100 mg powder for concentrate for solution for infusion, Fluorouracil Injection, 50 mg/ml, solution for injection, Ziihera 300 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion., Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, Oxaliplatin Hikma 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Xeloda 500 mg film-coated tablets, Xeloda 150 mg film-co

    Boehringer Ingelheim

    gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma

    phase 2 small molecule active

    1 trial

  36. Matching placebo tablets without active substance, BI 706321, BI 706321, BI 706321, STELARA 130 mg concentrate for solution for infusion, STELARA 90 mg solution for injection in pre-filled pen

    Boehringer Ingelheim

    Crohn`s Disease (CD)

    phase 2 small molecule active

    1 trial

  37. Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, BI 1810631, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Boehringer Ingelheim

    locally advanced or metastatic NSCLC

    phase 2 small molecule active

    1 trial

  38. Placebo matching BI 764198, BI 764198

    Boehringer Ingelheim

    Proteinuric kidney diseases

    phase 2 small molecule active

    1 trial

  39. Placebo to BI 765423, BI 765423

    Boehringer Ingelheim

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  40. Spesolimab

    Boehringer Ingelheim

    Generalized Pustular Psoriasis

    phase 2 small molecule active

    1 trial

  41. Tipranavir

    Boehringer Ingelheim

    HIV Infections

    phase 2 small molecule completed

    1 trial

  42. Vicadrostat

    Boehringer Ingelheim

    Chronic Kidney Disease

    phase 2 small molecule active

    1 trial

  43. linagliptin low dose

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  44. ribavirin (RBV)

    Boehringer Ingelheim

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  45. tiotropium-bromide

    Boehringer Ingelheim

    Asthma

    phase 2 small molecule completed

    1 trial

  46. "A study in healthy people to test how 2 different formulations of a combination treatment (vicadrostat and empagliflozin) are taken up in the body and how food influences the amount of the medicines in the blood"

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  47. "A study to test how well BI 3000202 is tolerated by people with type 1 interferonopathies"

    Boehringer Ingelheim

    Type 1 interferonopathies

    phase 1 other active

    1 trial

  48. A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

    Boehringer Ingelheim

    non-small cell lung cancer or, melanoma, head and neck squamous cell carcinoma

    phase 1 other active

    1 trial

Frequently asked questions

How many pipeline programs does Boehringer Ingelheim have?

193 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.